(Q38298241)

1 September 2017

1 reference

title

Clinical blockade of PD1 and LAG3--potential mechanisms of action (English)

1 reference

1 September 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25534622%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Linh T Nguyen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25534622%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

1 January 2015

1 reference

Nature Reviews Immunology

1 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25534622%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25534622%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25534622%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

45-56

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25534622%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference

Molecular signature of CD8+ T cell exhaustion during chronic viral infection.

31 March 2020

1 reference

Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence

31 March 2020

1 reference

Restoring function in exhausted CD8 T cells during chronic viral infection

31 March 2020

1 reference

PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection

31 March 2020

1 reference

Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction

31 March 2020

1 reference

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

31 March 2020

1 reference

Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection

31 March 2020

1 reference

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

31 March 2020

1 reference

Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

31 March 2020

1 reference

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination

31 March 2020

1 reference

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients

31 March 2020

1 reference

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

31 March 2020

1 reference

Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation

31 March 2020

1 reference

CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction

31 March 2020

1 reference

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.

31 March 2020

1 reference

PD-1 dependent exhaustion of CD8+ T cells drives chronic malaria.

31 March 2020

1 reference

HTLV-1 specific CD8+ T cell function augmented by blockade of 2B4/CD48 interaction in HTLV-1 infection

31 March 2020

1 reference

Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients

31 March 2020

1 reference

Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization

31 March 2020

1 reference

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

31 March 2020

1 reference

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

31 March 2020

1 reference

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

31 March 2020

1 reference

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.

31 March 2020

1 reference

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

31 March 2020

1 reference

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

31 March 2020

1 reference

Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2

31 March 2020

2 references

31 March 2020

12 December 2020

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

2 references

31 March 2020

12 December 2020

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

1 reference

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

31 March 2020

1 reference

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

31 March 2020

1 reference

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

31 March 2020

1 reference

PD-1 and its ligands in tolerance and immunity

31 March 2020

1 reference

The PD-1-PD-L pathway in immunological tolerance

31 March 2020

1 reference

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

31 March 2020

1 reference

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

31 March 2020

1 reference

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

31 March 2020

1 reference

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer

31 March 2020

1 reference

A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection

31 March 2020

1 reference

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

31 March 2020

1 reference

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

31 March 2020

1 reference

Nivolumab plus ipilimumab in advanced melanoma

31 March 2020

1 reference

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

31 March 2020

1 reference

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

31 March 2020

1 reference

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

31 March 2020

1 reference

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

31 March 2020

1 reference

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

31 March 2020

1 reference

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

31 March 2020

1 reference

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

31 March 2020

1 reference

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

31 March 2020

1 reference

Programmed death ligand-1 expression in non-small cell lung cancer

31 March 2020

1 reference

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

31 March 2020

1 reference

PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival

31 March 2020

1 reference

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

31 March 2020

1 reference

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

31 March 2020

1 reference

The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands

31 March 2020

1 reference

Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development.

31 March 2020

1 reference

Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy

31 March 2020

1 reference

PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice.

31 March 2020

1 reference

Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

31 March 2020

1 reference

Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis

31 March 2020

1 reference

PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells

31 March 2020

1 reference

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

31 March 2020

1 reference

B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis

31 March 2020

1 reference

Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysis

31 March 2020

1 reference

Endothelial Programmed Death-1 Ligand 1 (PD-L1) Regulates CD8 + T-Cell–Mediated Injury in the Heart

31 March 2020

1 reference

Programmed death ligand 2 in cancer-induced immune suppression.

31 March 2020

1 reference

RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance

31 March 2020

1 reference

PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis

31 March 2020

1 reference

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

31 March 2020

1 reference

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer

31 March 2020

1 reference

Inhibitory phenotype of HBV-specific CD4+ T-cells is characterized by high PD-1 expression but absent coregulation of multiple inhibitory molecules

31 March 2020

1 reference

CD4⁺ follicular helper T cell infiltration predicts breast cancer survival

31 March 2020

1 reference

PD-1 on dendritic cells impedes innate immunity against bacterial infection

31 March 2020

1 reference

Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection

31 March 2020

1 reference

Myeloid-derived suppressor cells regulate immune response in patients with chronic hepatitis B virus infection through PD-1-induced IL-10.

31 March 2020

1 reference

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

31 March 2020

1 reference

Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation

31 March 2020

1 reference

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

31 March 2020

1 reference

Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis

31 March 2020

1 reference

PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection

31 March 2020

1 reference

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

31 March 2020

1 reference

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

31 March 2020

1 reference

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

31 March 2020

1 reference

Role of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell death gene-1high germinal center-associated subpopulation.

31 March 2020

1 reference

PD-1 is a novel regulator of human B-cell activation

31 March 2020

1 reference

Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo

31 March 2020

1 reference

Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques.

31 March 2020

1 reference

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

31 March 2020

1 reference

Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction

31 March 2020

1 reference

B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism.

31 March 2020

1 reference

Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor

31 March 2020

1 reference

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

31 March 2020

1 reference

LAG-3, a novel lymphocyte activation gene closely related to CD4

31 March 2020

1 reference

Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3).

31 March 2020

1 reference

The CD4-like molecule LAG-3, biology and therapeutic applications

31 March 2020

1 reference

Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes

31 March 2020

1 reference

Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo

31 March 2020

1 reference

On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infection

31 March 2020

1 reference

Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection

31 March 2020

1 reference

T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts

31 March 2020

1 reference

LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems

31 March 2020

1 reference

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

31 March 2020

1 reference

Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma

31 March 2020

1 reference

Role of LAG-3 in regulatory T cells.

31 March 2020

1 reference

Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation

31 March 2020

1 reference

Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells

31 March 2020

1 reference

Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223)

31 March 2020

1 reference

MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis.

31 March 2020

1 reference

A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells

31 March 2020

1 reference

Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity

31 March 2020

1 reference

A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors

31 March 2020

1 reference

IMP321 (sLAG-3) safety and T cell response potentiation using an influenza vaccine as a model antigen: a single-blind phase I study

31 March 2020

1 reference

A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma

31 March 2020

1 reference

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

31 March 2020

1 reference

MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial

31 March 2020

1 reference

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

31 March 2020

1 reference

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

31 March 2020

1 reference

PD-1 blockade induces responses by inhibiting adaptive immune resistance

31 March 2020

1 reference

Nivolumab in previously untreated melanoma without BRAF mutation

31 March 2020

1 reference

Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses

31 March 2020

1 reference

PubMed

12 December 2020

Activation of human lymphocytes by a monoclonal antibody to B lymphoblastoid cells; molecular mass and distribution of binding protein

1 reference

PubMed

12 December 2020

Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity

1 reference

PubMed

12 December 2020

Identifiers

DOI

10.1038/NRI3790

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25534622%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference